Myasthenic disorders Flashcards

1
Q

Myasthenia gravis definition

A

autoimmune disorder of the neuromuscular junction with impairment of the signal transmission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What 2 autoantibodies could be present in MG?

A

acetylcholine receptor (AChR)
muscle specific kinase (MuSK)
seronegative MG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

AChR MG epidemiology

A

bimodal distribution
peaks young and old
earlier onset more common in women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MuSK MG epidemiology

A

one peak later in life
geographical distribution according to distance from the equator (most prevalent in mediterranean countries)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

MG clinical features

A

fluctuating weakness and fatigability of the skeletal muscles:
- ocular
- generalised
- generalised + bulbar

limb weakness usually symmetric and more proximal
bulbar = dysphagia, dysarthria, dysphonia, dyspnoea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is a life-threatening complication of MG?

A

myasthenic crisis - acute restrictive respiratory failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Clinical subtypes of AChR MG?

A

early-onset: <40-50y, female predominance, associated with thymic hyperplasia

late-onset: >50y, male predominance, thymic pathology rare

thymoma-associated: paraneoplastic subtype, no gender predominance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What subtype are the autoantibodies in AChR-MG? How does this block receptor function

A

IgG1, 2 and 3

  • strong interchain bonds between the 2 Fc parts of the IgG
  • divalent binding of the antibody to their antigen
  • internalisation of the antigen
  • complement activation
  • block of the receptor function
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What subtype are the autoantibodies in MuSK-MG? How does this block receptor function

A

Mainly IgG4 subclass

  • monovalent binding to the antigen
  • no complement activation
  • no internalisation of the target molecule
  • direct blocking effect on MuSK function
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Thymus normal function

A

promotes normal development of T lymphocytes

  • T cells undergo positive and negative selection according to their ability to react to the antigen presenting cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What happens to the thymus in myasthenia gravis?

A

lymphofollicular hyperplasia of the thymus can be detected in early-onset MG:
- increased number of germinal centres and lymphoid follicles
- MHC class 2 expressing thymic epithelial cells present the unfolded AChR subunits and activate auto-reactive CD4+ T cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Where does muscle weakness start and spread to in Lambert Eaton Myasthenic syndrome?

A

usually starts on pelvic girdle, then spreads to upper limbs and finally to oculobulbar muscles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What lung cancer is Lambert Eaton Myasthenic syndrome associated with?

A

small cell lung cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which antibodies are present in Lambert Eaton myasthenic syndrome?

A

antibodies against the pre-synaptic voltage-gated calcium channel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Lambert Eaton myasthenic syndrome treatment

A

3,4-Diaminopyridine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Neuromuscular junction disease differential diagnoses to consider

A

Botulism poisoning
Motor neuron disease
Guillain Barre syndrome

17
Q

How can AChR and MuSK antibodies be detected?

A

radioimmunoprecipitation assay (RIA)

18
Q

AChR MG treatment

A

ACh-esterase inhibitors (pyridostigmine) - increases availability of acetylcholine in synaptic cleft

steroids

immunosuppressive therapies (azathioprine, mycophenolate, cyclosporin) - used as steroid-sparing agents

thymectomy within 5 years

IVIg and plasmapheresis in treatment of acute and life-threatening relapses

19
Q

MuSk-MG treatment options

A

AChR-esterase inhibitors ineffective and could exacerbate symptoms

steroids = 1st line, higher doses than AChR-MG

thymectomy of no benefit as no association with thymic pathology observed
IVIg and plasmapheresis in acute and severe relapses

CD-20 depletion with rituximab:
- reduced antibody titres
- depletion of short-lived Ig4-producing plasma cells
- repopulation of regulatory B cells after treatment

20
Q
A